Regeneron Pharmaceuticals Inc (REGN)

Debt-to-equity ratio

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Long-term debt	US$ in thousands	1,984,400	1,982,900	1,981,400	1,980,000	1,978,500
Total stockholders’ equity	US$ in thousands	29,353,600	25,973,100	22,664,000	18,768,800	11,025,300
Debt-to-equity ratio		0.07	0.08	0.09	0.11	0.18

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,984,400K ÷ $29,353,600K
= 0.07

Regeneron Pharmaceuticals Inc's debt-to-equity ratio has exhibited a declining trend over the past five years based on the provided data. As of December 31, 2020, the ratio stood at 0.18, indicating that the company had $0.18 in debt for every $1 of equity. This ratio decreased to 0.11 by December 31, 2021, suggesting a reduction in debt relative to equity. Subsequently, the ratio continued to decline to 0.09 by December 31, 2022, further improving the company's leverage position.

By December 31, 2023, the debt-to-equity ratio fell to 0.08, signaling a sustained trend of efficient capital structure management by Regeneron Pharmaceuticals Inc. The most recent data point as of December 31, 2024, shows the ratio at 0.07, indicating a prudent level of indebtedness compared to shareholder equity.

Overall, the decreasing trend in the debt-to-equity ratio reflects Regeneron Pharmaceuticals Inc's efforts to reduce its reliance on debt financing and strengthen its financial position through enhanced equity contributions. This improving ratio suggests a healthier balance sheet structure and potentially lowers financial risk for the company.